Blue Sky Biotech, Inc.

Scott worked for five years in the metabolic diseases division of Sandoz Research Institute (now Novartis Institutes for BioMedical Research) where he was involved in the design, development and deployment of automated, cell-based, high-throughput screens for anti-diabetic compounds.

Scott received his doctorate from Dartmouth Medical School, Department of Microbiology and Immunology, for his work in biochemically purifying and characterizing a human protein complex (NELF) which represses RNA polymerase II transcriptional elongation and is specifically overcome by the HIV-1 Tat protein.

As a postdoctoral fellow, Scott joined the lab of Dr. Gustav Lienhard in the Biochemistry Department at Dartmouth. His research there focused on the insulin signaling pathway and led to the identification and characterization of several novel substrates of protein kinase B (Akt).